| 2.36 -0.25 (-9.58%) | 03-20 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 3.11 |
1-year : | 3.46 |
| Resists | First : | 2.66 |
Second : | 2.97 |
| Pivot price | 2.57 |
|||
| Supports | First : | 2.17 |
Second : | 1.8 |
| MAs | MA(5) : | 2.54 |
MA(20) : | 2.54 |
| MA(100) : | 19.68 |
MA(250) : | 37.86 |
|
| MACD | MACD : | -0.5  |
Signal : | -0.7 |
| %K %D | K(14,3) : | 39.4 |
D(3) : | 45.3 |
| RSI | RSI(14): 33.4 |
|||
| 52-week | High : | 311.35 | Low : | 2.09 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ GRI ] has closed above bottom band by 20.7%. Bollinger Bands are 95.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 53 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 2.64 - 2.66 | 2.66 - 2.67 |
| Low: | 2.33 - 2.34 | 2.34 - 2.36 |
| Close: | 2.34 - 2.36 | 2.36 - 2.38 |
GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase IIa clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis. The company's portfolio also includes GRI-0803, a novel oral agonist of type 2 Natural Killer T cells that is in preclinical development for the treatment of autoimmune disorders; a proprietary library of 500+ compounds; and GRI-0124 and GRI-0729 for balance inflammatory immune responses. GRI Bio, Inc. was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.
Fri, 20 Mar 2026
AI Investing Insights - Official Homepage - Intellectia AI™ - Intellectia AI
Wed, 28 Jan 2026
GRI Bio Reports Positive Study Results For Chronic Lung Disease, But Stock Slumps 20% — What Happened? - Stocktwits
Mon, 26 Jan 2026
New GRI Bio patent covers compounds for inflammatory and autoimmune diseases - Stock Titan
Wed, 21 Jan 2026
GRI Bio Announces Reverse Stock Split - GlobeNewswire
Wed, 21 Jan 2026
GRI Bio stock falls after announcing 1-for-28 reverse split - Investing.com
Thu, 15 Jan 2026
GRI Bio shareholders approve reverse stock split and report Nasdaq compliance - Investing.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 1 (M) |
| Shares Float | 1 (M) |
| Held by Insiders | 0.5 (%) |
| Held by Institutions | 0.1 (%) |
| Shares Short | 156 (K) |
| Shares Short P.Month | 25 (K) |
| EPS | -121.81 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 12.06 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -104 % |
| Return on Equity (ttm) | -238.2 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -8.26 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -10 (M) |
| Levered Free Cash Flow | -5 (M) |
| PE Ratio | -0.02 |
| PEG Ratio | 0 |
| Price to Book value | 0.19 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.34 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|